Screener
Crinetics Pharmaceuticals CRNX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's total costs & expenses?
- Crinetics Pharmaceuticals (CRNX) reported total costs & expenses of $151.11M in Q1 2026.
- How has Crinetics Pharmaceuticals's total costs & expenses changed year-over-year?
- Crinetics Pharmaceuticals's total costs & expenses increased by 35.2% year-over-year, from $111.77M to $151.11M.
- What does total costs & expenses mean?
- This represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period, including research and development, selling, general, and administrative expenses. It serves as a primary indicator of the company's total burn rate and operational scale. Monitoring this metric is essential for assessing the efficiency of resource allocation in a clinical-stage pharmaceutical environment.
Ask your AI about Crinetics Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude